S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
NASDAQ:ACAD

ACADIA Pharmaceuticals - ACAD Stock Forecast, Price & News

$18.05
-0.01 (-0.06%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$17.63
$18.15
50-Day Range
$14.11
$18.27
52-Week Range
$12.24
$28.06
Volume
1.24 million shs
Average Volume
1.91 million shs
Market Capitalization
$2.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.29

ACADIA Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
23.5% Upside
$22.29 Price Target
Short Interest
Bearish
6.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.30) to ($0.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

642nd out of 1,072 stocks

Pharmaceutical Preparations Industry

302nd out of 534 stocks

ACAD stock logo

About ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Stock News Headlines

ACADIA Pharmaceuticals Inc
Tracking Baker Brothers Portfolio - Q2 2022 Update
ACAD ACADIA Pharmaceuticals Inc.
Where ACADIA Pharmaceuticals Stands With Analysts
Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet
Acadia antipsychotic therapy snubbed by FDA panel
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Company Calendar

Last Earnings
8/08/2022
Today
10/05/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACAD
Employees
514
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.29
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+23.5%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
18 Analysts

Profitability

Net Income
$-167,870,000.00
Pretax Margin
-39.78%

Debt

Sales & Book Value

Annual Sales
$484.14 million
Book Value
$3.36 per share

Miscellaneous

Free Float
115,880,000
Market Cap
$2.92 billion
Optionable
Optionable
Beta
0.63

Key Executives

  • Mr. Stephen R. Davis J.D.Mr. Stephen R. Davis J.D. (Age 61)
    CEO & Director
    Comp: $1.03M
  • Dr. Srdjan R. Stankovic M.D.Dr. Srdjan R. Stankovic M.D. (Age 65)
    M.S.P.H., Pres
    Comp: $933.1k
  • Mr. Mark C. Schneyer (Age 48)
    Exec. VP & CFO
    Comp: $555.49k
  • Mr. Brendan P. TeehanMr. Brendan P. Teehan (Age 53)
    Exec. VP, COO & Head of Commercial
    Comp: $486.47k
  • Mr. Austin D. KimMr. Austin D. Kim (Age 58)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $559.24k
  • Mr. James K. KiharaMr. James K. Kihara (Age 41)
    VP, Chief Accounting Officer & Corp. Controller
  • Mr. Bob Mischler
    Sr. VP of Strategy & Technology Operations
  • Mr. Mark C. Johnson
    VP of Investor Relations
  • Ms. Julie Fisher
    Sr. VP of Marketing & Commercial Strategy
  • Ms. Holly Valdiviez
    Sr. VP & Head of Sales













ACAD Stock - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View ACAD analyst ratings
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price forecast for 2022?

18 Wall Street research analysts have issued 1-year price objectives for ACADIA Pharmaceuticals' shares. Their ACAD share price forecasts range from $10.00 to $35.00. On average, they predict the company's stock price to reach $22.29 in the next twelve months. This suggests a possible upside of 23.5% from the stock's current price.
View analysts price targets for ACAD
or view top-rated stocks among Wall Street analysts.

How have ACAD shares performed in 2022?

ACADIA Pharmaceuticals' stock was trading at $23.34 at the start of the year. Since then, ACAD stock has decreased by 22.7% and is now trading at $18.05.
View the best growth stocks for 2022 here
.

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ACAD earnings forecast
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings results on Monday, August, 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.04. The biopharmaceutical company earned $134.56 million during the quarter, compared to the consensus estimate of $130.06 million. ACADIA Pharmaceuticals had a negative net margin of 39.93% and a negative trailing twelve-month return on equity of 41.18%. The company's revenue was up 16.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.27) EPS.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $510.00 million-$540.00 million, compared to the consensus revenue estimate of $531.12 million.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $18.05.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $2.92 billion and generates $484.14 million in revenue each year. The biopharmaceutical company earns $-167,870,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

The company employs 514 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.

This page (NASDAQ:ACAD) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.